NewsBenzinga니키 바이오솔루션즈의 디아미알 바이오사이언스 자회사, 뉴욕주 보건부로부터 APOE 유전자형 검사에 대한 임상 실험실 평가 프로그램 테스트 승인 획득 니키 바이오솔루션즈의 디아미알 바이오사이언스 자회사, 뉴욕주 보건부로부터 APOE 유전자형 검사에 대한 임상 실험실 평가 프로그램 테스트 승인 획득 Benzinga 2026.10.26 13:16 (GMT+0) Open on Benzinga Other news AEON Biopharma Q3 EPS $0.01 Beats $(0.08) Estimate STOP-HS1 And STOP-HS2 Trials Evaluating Safety And Efficacy Of Povofortay In Patients With Moderate To Severe HS Met The Primary Endpoint Cable One Receives Non-Compliance Notice From NYSE Cadiz Q3 EPS $(0.18) Misses $(0.14) Estimate, Sales $1.572M Miss $2.710M Estimate MDU Resources Anticipates Issuing Equity Of ~$70M In 2027 And $100M In 2028 To Support Near-Term Capital Expenditures PagSeguro Digital Q3 Adj. EPS $0.43 Beats $0.41 Estimate, Sales $989.696M Miss $996.200M Estimate
STOP-HS1 And STOP-HS2 Trials Evaluating Safety And Efficacy Of Povofortay In Patients With Moderate To Severe HS Met The Primary Endpoint
MDU Resources Anticipates Issuing Equity Of ~$70M In 2027 And $100M In 2028 To Support Near-Term Capital Expenditures